SPatial Analysis of Cancer Evolution in the Tumour Immune MicroEnvironment

Projektinformationen

SPACETIME

ID Finanzhilfevereinbarung: 101136552

DOI

10.3030/101136552

EK-Unterschriftsdatum 3 Juni 2024

Startdatum 1 August 2024

Enddatum 31 Juli 2029

Finanziert unter

• Health

Gesamtkosten

€ 11 824 365,25

EU-Beitrag

€ 11 801 347,00

Koordiniert durch

STICHTING AMSTERDAM UMC
Netherlands

CORDIS bietet Links zu öffentlichen Ergebnissen und Veröffentlichungen von HORIZONT-Projekten.

Links zu Ergebnissen und Veröffentlichungen von RP7-Projekten sowie Links zu einigen Typen spezifischer Ergebnisse wie Datensätzen und Software werden dynamisch von OpenAIRE abgerufen.

Leistungen

Documents, reports (8)

Boards

SAP established

Common Workplan

Common work plan for scientific collaboration under the “Understanding (tumour-host interactions)”cluster .

Common video and/or a common cluster brochure
PDE

Plan for dissemination and exploitation incl. communication activities

"Conclusions Cluster Meeting #1"

Conclusions of common annual meeting of the “Understanding (tumour-host interactions)” cluster: Year 1

Impact Board

Formation of the Impact Board and set calendar meeting for the full duration of the project

Handbook

Project handbook

"Policy Brief Cluster Meeting #1"

Policy brief formulating recommendations based on the research and innovation strand of the “Understanding (tumour-host interactions)”annual cluster meeting: Year 1

Websites, patent fillings, videos etc. (1)

SPACETIME Website

Website dedicated to the project.

Other (2)

Midterm recruitment report SPACETIME Cohort

This report is due when 50% of the study population is recruited. The report shall include an overview of the number of recruited participants by clinical sites, any problems in recruitment and, if applicable, a detailed description of implemented and planned measures to compensate for any incurred delays.

Status of sample collection SPACETIME Cohort

A report on status of sample collection from mouse models and human patients, describing the number of samples, type of samples (e.g. frozen, FFPE, blood), purpose for analysis (which platforms), any problems encountered and (estimated) date of completion.

Veröffentlichungen

Peer reviewed articles (3)

Immune-modulating effects on tumor-draining lymph nodes of neoadjuvant chemoradiotherapy combined with dual immunotherapy in patients with T3-4N0-2 NSCLC

Autoren: Ezgi B Ulas, Sofie J I Koomen, Anne Vrijmoet, Ilias Houda, H Ibrahim Korkmaz, Chris Dickhoff, Idris Bahce, Suresh Senan, Tanja D de Gruijl, Marieke F Fransen, Teodora Radonic, Febe van Maldegem, Famke L Schneiders
Veröffentlicht in: Journal for ImmunoTherapy of Cancer, Ausgabe 13, 2025, ISSN 2051-1426
Herausgeber: BMJ
DOI: 10.1136/JITC-2025-013237

Establishment and characterization of an orthotopic implanted lung cancer model to mimic human tumor structure, microenvironment, and metastatic spread

Autoren: Beñat Picabea, Daniel Orive, Covadonga Rodríguez, Miren Mailharin, María Sangüesa, Maeva Houry, Andrea Arricibita, Mirari Echepare, Ane Álava, Cristina Viu-Idocin, Alfonso Calvo, Joaquín Fernández-Irigoyen, Enrique Santamaría, Mikel Ariz, Luis M. Montuenga, Karmele Valencia
Veröffentlicht in: Translational Lung Cancer Research, Ausgabe 14, 2025, ISSN 2218-6751
Herausgeber: AME Publishing Company
DOI: 10.21037/TLCR-2025-871

Spatial multiplex analysis of lung cancer reveals that regulatory T cells attenuate KRAS-G12C inhibitor–induced immune responses

Autoren: Megan Cole; Panayiotis Anastasiou; Claudia Lee; Xiaofei Yu; Andrea de Castro; Jannes Roelink; Chris Moore; Edurne Mugarza; Martin Jones; Karishma Valand; Sareena Rana; Emma Colliver; Mihaela Angelova; Katey S. S. Enfield; Alastair Magness; Asher Mullokandov; Gavin Kelly; Tanja D. de Gruijl; Miriam Molina-Arcas; Charles Swanton; Julian Downward; Febe van Maldegem
Veröffentlicht in: Science Advances, 2024, ISSN 2375-2548
Herausgeber: American Association for the Advancement of Science
DOI: 10.25418/CRICK.27605526.V1